Factor VII or VIIa-like molecules

Details Factor VII or VIIa-like molecules Factor VII or VIIa-like molecules

2006-06-26

2008-08-19

Tate, Christopher R. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000

Reexamination Certificate

active

07414022

ABSTRACT:
Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

REFERENCES:
patent: 4784950 (1988-11-01), Hagen et al.
patent: 4904584 (1990-02-01), Shaw
patent: 5041376 (1991-08-01), Gething et al.
patent: 5093317 (1992-03-01), Lewis et al.
patent: 5180583 (1993-01-01), Hedner
patent: 5225537 (1993-07-01), Foster
patent: 5258288 (1993-11-01), Wydro et al.
patent: 5288629 (1994-02-01), Berkner
patent: 5460950 (1995-10-01), Barr et al.
patent: 5504064 (1996-04-01), Morrisey et al.
patent: 5516640 (1996-05-01), Watanabe et al.
patent: 5580560 (1996-12-01), Nicolaisen et al.
patent: 5648254 (1997-07-01), Mulvihill et al.
patent: 5788965 (1998-08-01), Berkner et al.
patent: 5817788 (1998-10-01), Berkner et al.
patent: 5824634 (1998-10-01), Merchant
patent: 5824639 (1998-10-01), Berkner
patent: 5833982 (1998-11-01), Berkner et al.
patent: 5837843 (1998-11-01), Smirnov et al.
patent: 5847085 (1998-12-01), Esmon et al.
patent: 5861374 (1999-01-01), Berkner et al.
patent: 5891843 (1999-04-01), Turecek et al.
patent: 5965425 (1999-10-01), Barr et al.
patent: 5986079 (1999-11-01), Barr et al.
patent: 6013620 (2000-01-01), Turecek et al.
patent: 6017882 (2000-01-01), Nelsestuen
patent: 6100061 (2000-08-01), Reiter et al.
patent: 6423826 (2002-07-01), Nelsestuen et al.
patent: 6475725 (2002-11-01), Reiter et al.
patent: 6693075 (2004-02-01), Nelsestuen
patent: 6747003 (2004-06-01), Nelsestuen
patent: 6762286 (2004-07-01), Nelsestuen
patent: 6806063 (2004-10-01), Pedersen et al.
patent: 6903069 (2005-06-01), Pingel et al.
patent: 7026524 (2006-04-01), Persson et al.
patent: 7220837 (2007-05-01), Nelsestuen
patent: 2003/0100506 (2003-05-01), Nelsestuen
patent: 2003/0100740 (2003-05-01), Persson et al.
patent: 2003/0104978 (2003-06-01), Persson et al.
patent: 2003/0211094 (2003-11-01), Nelsestuen
patent: 2003/0211460 (2003-11-01), Nelsestuen
patent: 2005/0164932 (2005-07-01), Haaning
patent: 2006/0019336 (2006-01-01), Pedersen
patent: 2006/0111282 (2006-05-01), Haaning
patent: 2006/0166874 (2006-07-01), Haaning
patent: 2006/0228782 (2006-10-01), Pedersen
patent: 2006/0240524 (2006-10-01), Pedersen
patent: 2006/0240525 (2006-10-01), Pedersen
patent: 2006/0240526 (2006-10-01), Haaning
patent: 2006/0241041 (2006-10-01), Haaning
patent: 2006/0252127 (2006-11-01), Pedersen
patent: 2006/0252128 (2006-11-01), Haaning
patent: 2006/0252689 (2006-11-01), Pedersen
patent: 2006/0252690 (2006-11-01), Pedersen
patent: 2006/0258585 (2006-11-01), Pedersen
patent: 2006/0270000 (2006-11-01), Haaning
patent: 2006/0270001 (2006-11-01), Haaning
patent: 2006/0270002 (2006-11-01), Haaning
patent: 2006/0276377 (2006-12-01), Haaning
patent: 2007/0054366 (2007-03-01), Andersen
patent: 2007/0117756 (2007-05-01), Haaning
patent: 2007/0142280 (2007-06-01), Pedersen
patent: 0 296 413 (1988-12-01), None
patent: 0 354 504 (1990-02-01), None
patent: 0 370 205 (1990-05-01), None
patent: 0 512 011 (1992-11-01), None
patent: WO 88/10295 (1988-12-01), None
patent: WO 91/11514 (1991-08-01), None
patent: WO 92/15686 (1992-09-01), None
patent: WO 94/27631 (1994-12-01), None
patent: WO 96/00577 (1996-01-01), None
patent: WO 98/32466 (1998-07-01), None
patent: WO 98/35026 (1998-08-01), None
patent: WO 99/03498 (1999-01-01), None
patent: WO 99/03887 (1999-01-01), None
patent: WO 99/20767 (1999-04-01), None
patent: WO 99/66031 (1999-12-01), None
patent: WO 00/26230 (2000-05-01), None
patent: WO 00/26354 (2000-05-01), None
patent: WO 00/28065 (2000-05-01), None
patent: WO 00/54787 (2000-09-01), None
patent: WO 00/66753 (2000-11-01), None
patent: WO 01/83725 (2001-11-01), None
patent: WO 02/02764 (2002-01-01), None
patent: WO 02/03075 (2002-01-01), None
patent: WO 02/22776 (2002-03-01), None
patent: WO 02/38162 (2002-05-01), None
patent: WO 03/093465 (2003-11-01), None
patent: WO 2004/029091 (2004-04-01), None
patent: WO 2004/083361 (2004-09-01), None
Cheung, W.F. et al., “Localization of a metal-dependent epitope to the amino terminal residues 33-40 of human factor IX”,Thrombosis Research, 80(5):419-427 (1995).
Database EMBL, “Gallus gallus anticoagulant protein C precursor (PROC) mRNA, complete cds”, Database Accession No. AF465270, Feb. 2, 2003.
Hedner, U. “NovoSeven as a universal haemostatic agent.”Blood Coagul. Fibrinolysis11 Suppl 1:S107-S111 (2000).
Higashi, S. et al. “Molecular mechanism of tissue factor-mediated acceleration of factor VIIa activity,”J. Biol. Chem.271(43):26569-74 (1996).
Iakhiaev, A. et al. “The role of catalytic cleft and exocite residues of factor VIIa for complex formation with tissue factor pathway inhibitor”,Thromb. Haemost.85(3):458-463 (2001).
Sorensen, B.B. et al. “Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor,”J. Biol. Chem.272(18):11863-11868 (1997).
Sridhara S. et al. “Activation of a recombinant human factor VII structural analogue alters its affinity of binding to tissue factor,”Am. J. Hematol.53(2):66-71 (1996).
Zhang E, et al. “Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutan”. J. Mo.l Biol. 1999;285(5):2089-2104.
Database Uniprot “Coalgulation Factor VII (EC 3.4.21.21) (Serum prothrombin converstion accelerator)”, Database Accesssion No. P22457 Aug. 1, 1991.
Bharadwaj, D., et al., “Factor VII Central—A Novel Mutation in the Catalytic Domain that Reduces Tissue Factor Binding, Impairs Activation by Factor XA, and Abolishes Amidolytic and Coagulant Activity,”J. Biological Chemistry271(48):30685-30691 (1996).
Bjoern, S., et al., “Human Plasma and Recombinant Factor VII—Characterization ofO-Glycosylations at Serine Residues 52 and 60 and Effects of Site-Directed Mutagenesis of Serine 52 to Alanine,”J. Biological Chemistry266(17):11051-11057 (1991).
Chang, J-Y., et al., “Replacing the First Epidermal Growth Factor-like Domain of Factor IX with That of Factor VII Enhances Activity In Vitro and in Canine Hemophilia B,”J. Clin. Invest.100(4):886-892 (1997).
Chang, Y-J., et al., “Engineered Recombinant Factor VII Q217Variants with Altered Inhibitor Specificities,”Biochemistry38:10940-10948 (1999).
Kemball-Cook, G., et al., “Coagulation Factor VII Gln100→ Arg—Amino Acid Substitution at the Epidermal Growth Factor 2-Protease Domain Interface Results in Severely Reduced Tissue Factor Binding and Procoagulant Function,”J. Biological Chemistry273(14):8516-8521 (1998).
Dickinson, C.D., et al., “Active Site Modification of Factor VIIa Affects Interactions of the Protease Domain with Tissue Factor,”J. Biological Chemistry272(32):19875-19879 (1997).
Dickinson, C.D. et al., “Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa,”Proc. Natl. Acad. Sci. USA93:14379-14384 (1996).
Huang, Q., et al., “Substrate Recognition by Tissue Factor-Factor VIIa—Evidence for Interaction of Residues Lys165and Lys166of Tissue Factor with the 4-Carboxyglutamate-Rich Domain of Factor X,”J. Biological Chemistry271(36):21752-21757 (1996).
Iino, M., et al., “Functional Consequences of Mutations in Ser-52 and Ser-60 in Human Blood Coagulation Factor VII,”Archives of Biochemistry and Biophysics352(2):182-192 (1998).
Jin, J., et al., “Factor VIIa's First Epidermal Growth Factor-like Domain's Role in Catalytic Activity,”Biochemistry38:1185-1192 (1999).
Kelly, C.R., et al., “Ca2+Binding to the First Epidermal Growth Factor Module of Coagulation Factor VIIa Is Important for Cofactor Interaction and Proteolytic Function,”J. Biological Chemistry272(28):17467-17472 (1997).
Leonard, B.J.N., et al., “Activation and Active Site Occupation Alter Co

Affiliated with

Also associated with

Rating

Factor VII or VIIa-like molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Factor VII or VIIa-like molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Factor VII or VIIa-like molecules will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4014704